Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.67 |
| ▸ | NPC1 | O15118 | 10/20 | 0.67 |
| ▸ | RAB9A | P51151 | 10/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.67 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.58 |
| ▸ | HPGD | P15428 | 9/20 | 0.58 |
| ▸ | MAPT | P10636 | 6/20 | 0.58 |
| ▸ | TP53 | P04637 | 6/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.58 |
| ▸ | GAA | P10253 | 4/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | GFER | P55789 | 2/20 | 0.58 |
| ▸ | GLA | P06280 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
| ▸ | CDK1 | P06493 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29567848 | 1.00 | ALDH1A1 (0.67) | ALDH1A1NPC1RAB9AKDM4EGPR55 | |
| SCHEMBL29071868 | 0.86 | ALDH1A1 (0.63) | ALDH1A1NPC1RAB9AKDM4EGPR55 | |
| SCHEMBL12861171 | 0.84 | ALDH1A1 (0.71) | ALDH1A1NPC1RAB9AKDM4EGPR55 | |
| SCHEMBL28118423 | 0.84 | ALDH1A1 (0.71) | ALDH1A1NPC1RAB9AKDM4EGPR55 | |
| SCHEMBL12861190 | 0.84 | NPC1 (0.74) | ALDH1A1NPC1RAB9AKDM4EGPR55 | |
| SCHEMBL2690716 | 0.84 | ALDH1A1 (0.51) | ALDH1A1NPC1RAB9AKDM4EGPR55 | |
| SCHEMBL3834420 | 0.82 | ALDH1A1 (0.68) | ALDH1A1NPC1RAB9AKDM4EGPR55 | |
| SCHEMBL1283869 | 0.82 | NPC1 (0.67) | ALDH1A1NPC1RAB9AKDM4EGPR55 | |
| SCHEMBL29946404 | 0.82 | ADORA2A (0.65) | ALDH1A1NPC1RAB9AKDM4EGPR55 | |
| SCHEMBL4496268 | 0.81 | ALDH1A1 (0.66) | ALDH1A1NPC1RAB9AKDM4EGPR55 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109928931-B | Sulfonamide derivative containing benzimidazole structure and preparation method and application thereof | 沈阳药科大学 | 2022-09-02 | — | — | CN | disclosed |
| CN-111039983-B | Preparation method and application of antibacterial drug | 赵洁 | 2022-04-15 | — | — | CN | disclosed |
| EP-2875005-B1 | N-(3-HETEROARYLARYL)-4-ARYLARYLCARBOXAMTDES AND ANALOGS AS HEDGEHOG PATHWAY INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS INC (CN) | 2020-11-11 | — | — | EP | disclosed |
| EP-2875005-B1 | N-(3-HETEROARYLARYL)-4-ARYLARYLCARBOXAMTDES AND ANALOGS AS HEDGEHOG PATHWAY INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS INC (CN) | 2020-11-11 | — | — | EP | disclosed |
| CN-108239068-B | Nicotinamide derivative and preparation method and application thereof | 沈阳药科大学 | 2020-09-08 | — | — | CN | disclosed |
| EP-3321261-B1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | CURIS INC (US) | 2020-06-17 | — | — | EP | disclosed |
| US-10676468-B2 | N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs as hedgehog pathway inhibitors and use thereof | IMPACT THERAPEUTICS, INC. (CN) | 2020-06-09 | — | — | US | disclosed |
| US-10676468-B2 | N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs as hedgehog pathway inhibitors and use thereof | IMPACT THERAPEUTICS, INC. (CN) | 2020-06-09 | — | — | US | disclosed |
| CN-111039983-A | Preparation method and application of antibacterial drug | 赵洁 | 2020-04-21 | — | — | CN | disclosed |
| EP-3354646-A1 | ISOINDOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Celgene Corporation (US) | 2018-08-01 | — | — | EP | disclosed |
| US-20120122865-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CELGENE CORPORATION | 2012-05-17 | — | — | US | disclosed |
| US-8129375-B2 | Isoindoline compounds and methods of their use | CELGENE CORPORATION (US) | 2012-03-06 | — | — | US | disclosed |
| EP-2358697-A1 | Isoindoline compounds for use in the treatment of cancer | CELGENE CORPORATION (US) | 2011-08-24 | — | — | EP | disclosed |
| US-20100204227-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CELGENE CORPORATION | 2010-08-12 | — | — | US | disclosed |
| WO-2010053732-A1 | ISOINDOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | CELGENE CORPORATION (US) | 2010-05-14 | — | — | WO | disclosed |
| EP-1482928-B1 | MEDIATORS OF HEDGEHOG SIGNALING PATHWAYS,COMPOSITIONS AND USES RELATED THERETO | CURIS INC (US) | 2009-09-23 | — | — | EP | disclosed |
| EP-1482928-A4 | MEDIATORS OF HEDGEHOG SIGNALING PATHWAYS,COMPOSITIONS AND USES RELATED THERETO | CURIS INC (US) | 2005-10-12 | — | — | EP | disclosed |
| US-20050085519-A1 | Mediators of hedgehog signaling pathways, compositions and uses related thereto | CURIS, INC. | 2005-04-21 | — | — | US | disclosed |
| EP-1482928-A2 | MEDIATORS OF HEDGEHOG SIGNALING PATHWAYS,COMPOSITIONS AND USES RELATED THERETO | Curis, Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003011219-A2 | MEDIATORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED THERETO | CURIS, INC. (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10676468-B2 | N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs as hedgehog pathway inhibitors and use thereof | SHH, GLI1, SMO | ALDH1A1 493/4885NPC1 1208/4885RAB9A 569/4885 |
| US-20100204227-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CPT1A, CYP11B2, NPC1 | ALDH1A1 674/4885NPC1 3/4885RAB9A 2154/4885 |
| US-20120122865-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CPT1A, CYP11B2, NPC1 | ALDH1A1 674/4885NPC1 3/4885RAB9A 2154/4885 |
| US-20050085519-A1 | Mediators of hedgehog signaling pathways, compositions and uses related thereto | SHH, SMO, GLI1 | ALDH1A1 4223/4885NPC1 3382/4885RAB9A 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.